AVIRAtea Pharmaceuticals, Inc.

5.430USD-2.86%Mkt Cap: 435.51M $P/E:

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the re…

Key Statistics

Company
Market Cap435.51M $
Enterprise Value210.86M $
Revenue (TTM)
Gross Profit-155.12M $
Net Income (TTM)-158.35M $
Revenue/Share
Last Price5.430 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees55
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)
P/E (Forward)-3.62
PEG
EV/EBITDA-1.15
EV/Revenue
P/S
P/B2.11
EPS (TTM)-1.99
EPS (Forward)-1.48
52W Range
2.78072% of range6.450
52W High6.450 USD
52W Low2.780 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-57.49%
ROA-50.23%
Growth
Revenue Growth
Earnings Growth
Cash Flow & Leverage
Operating CF-132.03M $
CapEx (TTM)
FCF Margin
FCF Yield-21.31%
Net Debt-219.04M $
Net Debt/EBITDA1.20
Balance Sheet
Debt/Equity0.00
Current Ratio8.13
Quick Ratio7.80
Book Value/Sh2.545 USD
Cash/Share2.736 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.417 USD
Upside (mean)+73.4%
Target Range7.000 USD11.25 USD
$7.000+73.4% to mean$11.25
# Analysts3
Ownership
Shares Out.80.20M
Float60.34M
Insiders13.37%
Institutions79.07%
Short Interest
Short Ratio19.6d
Short % Float12.14%
Short % Out.9.41%
Shares Short7.53M
Short (prev mo.)6.99M
Technical
SMA 504.770 (+13.8%)
SMA 2004.483 (+21.1%)
Beta0.27
S&P 52W Chg18.16%
Avg Vol (30d)332.06K
Avg Vol (10d)269.91K
Technical Indicators
RSI (14)64.3
MACD0.1699
MACD Signal0.1105
MACD Hist.+0.0594
BB Upper5.518 USD
BB Middle4.936 USD
BB Lower4.355 USD
BB Width23.54%
ATR (14)0.2775 USD
Vol Ratio (20d)0.54x